SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm
PR Newswire
LOS ANGELES, April 15, 2024
LOS ANGELES, April 15, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ: CKPT) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between March 10, 2021 and December 15, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 4, 2024.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Checkpoint failed to maintain appropriate controls over third-party manufacturers. The Company suffered from multiple issues with its third-party contract manufacturers for cosibelimab. These problems would impact the likelihood of cosibelimab achieving FDA approval. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Checkpoint, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-action-alert-the-schall-law-firm-encourages-investors-in-checkpoint-therapeutics-inc-with-losses-to-contact-the-firm-302116183.html
SOURCE The Schall Law Firm
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?